CriticalErgot alkaloid, 5-HT1B/1D and alpha-adrenoceptor agonist×Macrolide antibiotic
Updated · Methodology
Mechanism
Erythromycin inhibits the liver enzyme CYP3A4, and the Spanish summary of product characteristics (SmPC) calls it a moderate inhibitor of this enzyme (erythromycin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US dihydroergotamine labels list erythromycin among strong CYP3A4 inhibitors (dihydroergotamine labels, US Food and Drug Administration, FDA). CYP3A4 inhibition raises dihydroergotamine blood levels and with them the risk of vasospasm with ischaemia of the brain and limbs (FDA). With the strong inhibitor itraconazole, exposure to dihydroergotamine itself rose by 14–19%, while exposure to its active metabolite, an equally potent venoconstrictor, rose about 3- to 4-fold (dihydroergotamine labels, FDA). Post-marketing reports link erythromycin taken with ergotamine or dihydroergotamine to acute ergot toxicity with vasospasm and ischaemia of the limbs and other tissues, including the central nervous system (erythromycin SmPCs, AEMPS, and labels, FDA).
Symptoms
With excess dihydroergotamine, the muscles ache, the fingers and toes become numb, cold, pale or bluish, and pulses in the arms and legs weaken or disappear (dihydroergotamine labels, US Food and Drug Administration, FDA). Leg ischaemia causes cramping and pain in the legs or hips, heaviness or tightness in the leg muscles, burning or aching pain in the feet or toes at rest, and coldness or colour change in one or both legs. Brain ischaemia causes slurred speech and sudden weakness (dihydroergotamine labels, FDA). Myocardial and colonic ischaemia have also been reported. Severe poisoning causes nausea, vomiting, abdominal pain, respiratory depression, a rise and then usually a fall in blood pressure, confusion, delirium, seizures and coma (dihydroergotamine labels, FDA). Persistent vasospasm in people with poor circulation can lead to gangrene or death (dihydroergotamine labels, FDA).
Management
The combination is contraindicated. The Spanish erythromycin summaries of product characteristics (SmPCs), for both oral and intravenous forms, contraindicate erythromycin with ergotamine and dihydroergotamine (erythromycin SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS), and so do the US erythromycin labels (erythromycin labels, US Food and Drug Administration, FDA). The US dihydroergotamine labels, for their part, contraindicate strong CYP3A4 inhibitors and name erythromycin among them (dihydroergotamine labels, FDA). Dihydroergotamine is not in the Spanish medicines register. Tell the patient to stop dihydroergotamine and get emergency help at once if they develop cramping and pain in the legs, numbness, coldness or colour change in the legs, slurred speech or sudden weakness (dihydroergotamine labels, FDA). If both drugs have nevertheless been taken and signs of vasospasm appear, stop dihydroergotamine at once (dihydroergotamine labels, FDA). In overdose, stop dihydroergotamine, support and monitor vital functions, and observe the patient for at least 24 hours or for as long as symptoms persist. Warm the affected area, give vasodilators and provide nursing care to prevent tissue damage (dihydroergotamine labels, FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Erythrocin Lactobionate-IV (erythromycin lactobionate for injection) – prescribing information (2025)– FDA label, Hospira, DailyMed setid a96c405f-bd70-4bb4-719e-ac6a79dcc213, version 25, 10/2025, CONTRAINDICATIONS (ergotamine, dihydroergotamine), WARNINGS (QT Prolongation), PRECAUTIONS: Drug Interactions
- AEMPS: Ficha técnica: Eritromicina (nº registro 79380), sección 4.3 (2025)– AEMPS, CIMA, nº registro 79380, sección 4.3
- FDA: ATZUMI (dihydroergotamine) prescribing information (2026)– FDA, DailyMed setid 0982a44a-dc0c-75c0-e063-6394a90a6d6c, revisión 06/2026 (versión 3), secciones 4, 5.5, 5.6 y 7.2
- FDA: TRUDHESA (dihydroergotamine) prescribing information (2026)– FDA, DailyMed setid b81397b0-910d-4eb4-8fee-a9a3c9d94d63, revisión 09/2026 (versión 7), secciones 4 y 7.2
- FDA: E.E.S. (erythromycin ethylsuccinate) prescribing information (2025)– FDA, DailyMed, Carnegie Pharmaceuticals LLC, setid 91479d92-3bf3-4eb3-81bd-8ce4956d4347, revised 02/2025, Contraindications, Warnings – QT Prolongation, Precautions – Drug Interactions
- AEMPS: Ficha técnica: Eritromicina (nº registro 55771), sección 4.3 (2025)– AEMPS, CIMA, nº registro 55771 (Pantomicina 1 g polvo para solución para perfusión), revisión 09/2025, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Eritromicina (nº registro 58767), sección 4.3 (2025)– AEMPS, CIMA, nº registro 58767 (Pantomicina 100 mg/ml granulado para suspensión oral, Amdipharm), revisión 11/2025 (texto revisado 05/2024), secciones 4.3, 4.4 y 4.5